Share

October 18, 2016; 87 (16) Article

Calcium supplementation and risk of dementia in women with cerebrovascular disease

Jürgen Kern, Silke Kern, Kaj Blennow, Henrik Zetterberg, Margda Waern, Xinxin Guo, Anne Börjesson-Hanson, Ingmar Skoog, Svante Östling
First published August 17, 2016, DOI: https://doi.org/10.1212/WNL.0000000000003111
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
29883

Share

Article Information

vol. 87 no. 16 1674-1680
DOI: 
https://doi.org/10.1212/WNL.0000000000003111
PubMed: 
27534711
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received January 16, 2016
  • Accepted in final form July 5, 2016
  • First Published August 17, 2016.

Article Versions

Copyright & Usage: 
© 2016 American Academy of Neurology

Author Disclosures

    1. Jürgen Kern, MD, PhD*,
    2. Silke Kern, MD, PhD*,
    3. Kaj Blennow, MD, PhD,
    4. Henrik Zetterberg, MD, PhD,
    5. Margda Waern, MD, PhD,
    6. Xinxin Guo, MD, PhD,
    7. Anne Börjesson-Hanson, MD, PhD,
    8. Ingmar Skoog, MD, PhD‡ and
    9. Svante Östling, MD, PhD‡
  1. Jürgen Kern, MD, PhD*,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Silke Kern, MD, PhD*,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Associate Editor of Journal of Alzheimer's disease since 2016 without compensation.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Kaj Blennow, MD, PhD,
    4. Scientific Advisory Boards:

    1. Dr Blennow has served at advisory boards or as a consultant for Eli Lilly, IBL International, and Roche Diagnostics.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Fujirebio Europe

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Novartis

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. Co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. The Research Council, Sweden (project # 14002) and LUA/ALF project, V?stra G?talandsregionen, Sweden (project # ALFGBG-11019)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. The Torsten S?derberg Foundation at the royal Swedish Academy of Sciences, the Alzheimer Foundation, Sweden, the Stiftelsen f?r Gamla Tj?narinnor, Stockholm, Sweden and Hj?rnfonden, Sweden.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Henrik Zetterberg, MD, PhD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Journal of Alzheimer's Disease, Associate Editor Alzheimer's & Dementia, Associate Editor DADM, Associate Senior Editor

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. HZ is co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg.

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) The Swedish Research Council (K2010-63P-21562-01-4, K2011-61X-20401-05-6); (2) Swedish State Support for Clinical Research (ALFGBG-144341); (3) VINNOVA; (4) the Knut and Alice Wallenberg Foundation; (5) the European Research Council; and (6) Frimurarestiftelsen

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Margda Waern, MD, PhD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. Den suicidn?ra patienten (The suicidal patient). Studentlitteratur. receipt of royalties 2012-2016.

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Swedish Council for working life and social research Suicidal thoughts and attempts in women followed from mid- to late life. Grant number 2012-1138. PI. 2013-2014. Suicidality in suicide attempters. Swedish Research Council. grant number 2013-2699. PI 2014-2016. Suicidality in older women. King Gustaf V and Queen Victoria's Freemason Foundation. 2014-16. SCREAM: Acute suicidal episodes. Gothenburg Center for Person-centered Care. 2014. Suicidality in suicide attempters. Swedish Research Council. grant number 2011-299. PI 2012-2014. Sahlgrenska Studies on suicide. Swedish Research Council. grant number 2008-3139 Swedish Council for working life and social research A 41 year longitudinal population study on dementia and other disorders in women. Grant number 2008-1229.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Xinxin Guo, MD, PhD,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Anne Börjesson-Hanson, MD, PhD,
    8. Scientific Advisory Boards:

    1. Served on advisory board or DSMB for Kyowa Hakko Kirin and Ionis

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Consultant for Pfizer, Janssen-Cilag, Lundbeck, Novartis

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. Serve as investigator for clinical trials sponsored by Lilly, Novartis, Pfizer, ACImmune, Sanofiaentis

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Ingmar Skoog, MD, PhD‡ and
    9. Scientific Advisory Boards:

    1. Takeda

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Takeda Novartis

    Editorial Boards:

    1. American Journal of Geriatric psychiatry. Triage-Editor 2010- European Journal of Psychiatry. Editorial Board

    Patents:

    1. NONE

    Publishing Royalties:

    1. Dementia textbook Sweden 2003. Liber Text book in acute psychiatri. Studentlitteratur

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Takeda

    Speakers' Bureaus:

    1. Takeda

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1)The Swedish Research Council 11267, 825-2012-5041, 2013-8717, 2015-02830 PI 1994 until now (2) Swedish Research Council for Health, Working Life and Wellfare (2012-1138, 2013-1202, 2013-2300, 2013-2496, 2006-1506)PI, 1999 until now (3) Swedish Brain Power co-PI, 2005 until now

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. The Alzheimer's Association Zenith Award (ZEN-01-3151) The Alzheimer's Association Stephanie B. Overstreet Scholars (IIRG-00-2159) The Alzheimer's Association (IIRG-03-6168) The Bank of Sweden Tercentenary Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Svante Östling, MD, PhD‡
    10. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. FAS 2013-0475 1.500.000 swedish kr

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. 220.000 swedish kr. S?derstr?m K?nigska projektanslag

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neuropsychiatric Epidemiology (J.K., S.K., M.W., X.G., A.B.-H., I.S., S.O.) and Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology (S.K., K.B., H.Z.), Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; and UCL Institute of Neurology (H.Z.), London, UK.
  1. Correspondence to Dr. S. Kern: silke.kern{at}neuro.gu.se
View Full Text

Article usage

Article usage: August 2016 to February 2021

AbstractFullPdfSource
Aug 201673200101Highwire
Sep 20162804061Highwire
Oct 201625502673Highwire
Nov 20161118522Highwire
Dec 2016512416Highwire
Jan 20174321210Highwire
Feb 201733714Highwire
Mar 201728712Highwire
Apr 201730022Highwire
Apr 201751515pmc
May 201721911Highwire
May 2017123438pmc
Jun 201719102Highwire
Jun 2017121618pmc
Jul 201717700Highwire
Jul 201751724pmc
Aug 201716701Highwire
Aug 2017112937pmc
Sep 201717601Highwire
Sep 201762532pmc
Oct 201718713Highwire
Oct 2017136469pmc
Nov 201717401Highwire
Nov 2017252648328877pmc
Dec 201727901Highwire
Jan 201818911Highwire
Feb 201813532Highwire
Mar 201817811Highwire
Apr 201824021Highwire
Apr 201813119141pmc
May 201816516Highwire
Jun 201816110Highwire
Jun 20186134157pmc
Jul 201816000Highwire
Aug 201810800Highwire
Aug 20187118140pmc
Sep 201811310Highwire
Oct 201812000Highwire
Nov 201816921Highwire
Dec 201811500Highwire
Jan 20199021Highwire
Feb 20198202Highwire
Mar 20199310Highwire
Apr 201925211Highwire
May 20199600Highwire
Jun 20197913Highwire
Jul 201911500Highwire
Aug 20198211Highwire
Sep 20199532Highwire
Oct 201910641Highwire
Nov 201910510Highwire
Dec 201914602Highwire
Jan 202011700Highwire
Feb 20206711Highwire
Mar 20206300Highwire
Apr 20206510Highwire
May 20209200Highwire
Jun 202011700Highwire
Jul 202012011Highwire
Aug 202010800Highwire
Sep 202014622Highwire
Oct 202015111Highwire
Nov 202015010Highwire
Dec 202013821Highwire
Jan 202117140Highwire
Feb 202112353Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

  • Author response to Dr. Beale
    • Silke Kern, MD, PhD, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska A
    • J. Kern; K. Blennow; H. Zetterberg; M. Waern; X. Guo; A. B?rjesson-Hanson; I. Skoog; S. ?stling
    Submitted October 28, 2016
  • Methodology leads to unreliable results
    • David J. Beale, Clinical Pharmacist, CVS Health
    Submitted October 21, 2016
  • Author Response to Dr. Rosenberg
    • Silke Kern, MD, PhD, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska A
    • J. Kern, K. Blennow, H. Zetterberg, M. Waern, X. Guo, A. Borjesson-Hanson, I. Skoog, S. Ostling
    Submitted September 28, 2016
  • Calcium-associated dementia risk
    • Gilad Rosenberg, Medical Director, Clal Biotechnology Industries
    Submitted September 23, 2016
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Topics Discussed

Alert Me